Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health

J Law Med Ethics. 2013 Fall;41(3):571-80. doi: 10.1111/jlme.12066.


This paper explains how the current architecture of the pharmaceutical markets has created a misalignment of financial incentives and public health that is a central cause of harmful practices. It explores three possible solutions to address that misalignment: taxes, increased financial penalties, and drug pricing based on value. Each proposal could help to partly realign financial incentives and public health. However, because of the limits of each proposal, there is no easy solution to fixing the problem of financial incentives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Costs
  • Drug Industry* / economics
  • Drug Industry* / ethics
  • Humans
  • Private Sector
  • Public Health*
  • Scientific Misconduct / legislation & jurisprudence
  • Taxes
  • United States